Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy

Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy

Bibliográfalaš dieđut
Váldodahkkit:	Paulson, K, Schmitt, T, Egan, D, Voillet, V, Lahman, M, Wagener, F, Hunter, D, Muhlhauser, P, Hendrie, P, Yeung, C, Vigneron, N, Van Den Eynde, B, Bielas, J, Bar, M, Gottardo, R, Chapuis, A, Greenberg, P
Materiálatiipa:	Conference item
Almmustuhtton:	American Association for Cancer Research 2018

Geahča maid

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency
Dahkki: Lahman, MC, et al.
Almmustuhtton: (2022)

Tumor Immunoediting, from T Cell-Mediated Immune Surveillance to Tumor-Escape of Uterine Leiomyosarcoma
Dahkki: Hayashi, Takuma, et al.
Almmustuhtton: (2018)

Expression of tumour-specific antigens underlies cancer immunoediting
Dahkki: DuPage, Michel J., et al.
Almmustuhtton: (2012)

Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.
Dahkki: Hong, D, et al.
Almmustuhtton: (2008)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
Dahkki: Barreyro, L, et al.
Almmustuhtton: (2012)

Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML
Dahkki: Puram, Rishi V., et al.
Almmustuhtton: (2018)

The graft-versus-leukemia effect in AML
Dahkki: Sweeney, C, et al.
Almmustuhtton: (2019)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
Dahkki: Goodyear, O, et al.
Almmustuhtton: (2012)

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Dahkki: Kersemans, V, et al.
Almmustuhtton: (2008)

Learning from the proteasome: how to fine-tune cancer immunotherapy
Dahkki: Vigneron, N, et al.
Almmustuhtton: (2017)

Mechanisms of response and resistance to AML therapies
Dahkki: Stoilova, B, et al.
Almmustuhtton: (2020)

IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML
Dahkki: Chan, L, et al.
Almmustuhtton: (2004)

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Dahkki: van Galen, Peter, et al.
Almmustuhtton: (2020)

The role of AML secretome and bone marrow microenvironment in establishment and maintenance of leukaemia initiating cells
Dahkki: Ren, X
Almmustuhtton: (2023)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
Dahkki: Hoyle, C, et al.
Almmustuhtton: (1989)

Suppression Of Aml1/ETO Via siRNA Mediated Gene Knockdown And Its Effects On FOXO3 AND c-Myc Expression In Aml t (8,21) Cells
Dahkki: Ong, Si Min
Almmustuhtton: (2017)

Cytosolic processing governs TAP-independent presentation of a critical melanoma antigen
Dahkki: Vigneron, N, et al.
Almmustuhtton: (2018)

Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML.
Dahkki: Bereshchenko, O, et al.
Almmustuhtton: (2009)

IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
Dahkki: Chan, L, et al.
Almmustuhtton: (2005)

Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo.
Dahkki: Cai, Z, et al.
Almmustuhtton: (2000)

Integrating next-generation dendritic Cell vaccines into the current cancer immunotherapy landscape.
Dahkki: Garg, A, et al.
Almmustuhtton: (2017)

Generation, Phenotyping and Functional Analysis of Dendritic Cells (DC) Derived from Human Monocytes and Acute Myeloid Leukaemia (AML) Cells
Dahkki: Lim, Moon Nian
Almmustuhtton: (2004)

Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.
Dahkki: Di Genua, C, et al.
Almmustuhtton: (2019)

CYTOLOGICAL FEATURES WITH PROGNOSTIC-SIGNIFICANCE IN AML
Dahkki: Swirsky, D, et al.
Almmustuhtton: (1983)

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Dahkki: Bhatnagar, N, et al.
Almmustuhtton: (2016)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Dahkki: Freeman, SD, et al.
Almmustuhtton: (2023)

Functional differences between proteasome subtypes
Dahkki: Abi Habib, J, et al.
Almmustuhtton: (2022)

Shall we dance: evolving partnerships of targeted therapies for AML
Dahkki: Perl, AE, et al.
Almmustuhtton: (2022)

Cell-Intrinsic Depletion of AML1-ETO-Positive Pre-Leukemic HSCs By Kras Activating Mutation
Dahkki: Di Genua, C, et al.
Almmustuhtton: (2017)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
Dahkki: Grimwade, D, et al.
Almmustuhtton: (1999)

Mammalian cell lines expressing functional RNA polymerase II tagged with the green fluorescent protein.
Dahkki: Sugaya, K, et al.
Almmustuhtton: (2000)

Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
Dahkki: Hills, R, et al.
Almmustuhtton: (2018)

Gene expression profiling in MDS and AML: potential and future avenues.
Dahkki: Theilgaard-Mönch, K, et al.
Almmustuhtton: (2011)

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
Dahkki: Grimwade, D, et al.
Almmustuhtton: (1996)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
Dahkki: Peniket, A, et al.
Almmustuhtton: (1999)

Monoclonal antibodies differentiating between monocytic and nonmonocytic variants of AML.
Dahkki: Linch, D, et al.
Almmustuhtton: (1984)

Production of spliced peptides by the proteasome
Dahkki: Vigneron, N, et al.
Almmustuhtton: (2018)

Peptide splicing by the proteasome.
Dahkki: Vigneron, N, et al.
Almmustuhtton: (2017)

Navigating critical challenges associated with immunopeptidomics-based detection of proteasomal spliced peptide candidates
Dahkki: Lichti, CF, et al.
Almmustuhtton: (2022)

Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines
Dahkki: Josa-Culleré, L, et al.
Almmustuhtton: (2023)